| Recruitment status | Completed |
| Unique ID issued by UMIN | UMIN000005448 |
| Receipt No. | R000006118 |
| Scientific Title | A phase II study of intensity modulated radiation therapy (IMRT) with chemotherapy for loco-regionally advanced nasopharyngeal cancer (NPC) (JCOG1015, IMRT for NPC) |
| Date of disclosure of the study information | 2011/04/15 |
| Last modified on | 2022/08/30 (Ver. 9) |
| Basic information | ||
| Public title | A phase II study of intensity modulated radiation therapy (IMRT) with chemotherapy for loco-regionally advanced nasopharyngeal cancer (NPC) (JCOG1015, IMRT for NPC) | |
| Acronym | A phase II study of intensity modulated radiation therapy (IMRT) with chemotherapy for loco-regionally advanced nasopharyngeal cancer (NPC) (JCOG1015, IMRT for NPC) | |
| Scientific Title | A phase II study of intensity modulated radiation therapy (IMRT) with chemotherapy for loco-regionally advanced nasopharyngeal cancer (NPC) (JCOG1015, IMRT for NPC) | |
| Scientific Title:Acronym | A phase II study of intensity modulated radiation therapy (IMRT) with chemotherapy for loco-regionally advanced nasopharyngeal cancer (NPC) (JCOG1015, IMRT for NPC) | |
| Region |
|
|
| Condition | ||
| Condition | Nasopharyngeal cancer | |
| Classification by specialty |
|
|
| Classification by malignancy | Malignancy | |
| Genomic information | NO | |
| Objectives | |
| Narrative objectives1 | To evaluate the efficacy and the safety of chemoradiotherapy with Intensity Modulated Radiation Therapy (IMRT) in patients with clinical stage II-IVB nasopharyngeal cancer (UICC 7th edition, 2009) |
| Basic objectives2 | Efficacy |
| Basic objectives -Others | |
| Trial characteristics_1 | Confirmatory |
| Trial characteristics_2 | |
| Developmental phase | Phase III |
| Assessment | |
| Primary outcomes | Overall survival (%3-year overall survival for clinical stage II-IVB) |
| Key secondary outcomes | Progression-free survival (%3-year progression-free survival), locoregional progression-free surival (%3-year locoregional progression-free survival), location of first progression, %completion of protocol treatment, %grade 2 or more dry mouth (evaluated at the 1st, 2nd , 3rd year from IMRT start, CTCAE ver4.0), adverse events |
| Base | |
| Study type | Interventional |
| Study design | |
| Basic design | Single arm |
| Randomization | Non-randomized |
| Randomization unit | |
| Blinding | Open -no one is blinded |
| Control | Historical |
| Stratification | |
| Dynamic allocation | |
| Institution consideration | |
| Blocking | |
| Concealment | |
| Intervention | ||
| No. of arms | 1 | |
| Purpose of intervention | Treatment | |
| Type of intervention |
|
|
| Interventions/Control_1 | Concurrent chemoradiotherapy with two-step IMRT (70 Gy/ 35 fr/ 47 days) and three cycles of cisplatin (80 mg/m2, day 1, q3w) follwed by three cycles of adjuvant chemotherapy with 5-FU (700 mg/m2, day 1-5) plus cisplatin (70 mg/m2, day 1) repeated every 4 weeks. | |
| Interventions/Control_2 | ||
| Interventions/Control_3 | ||
| Interventions/Control_4 | ||
| Interventions/Control_5 | ||
| Interventions/Control_6 | ||
| Interventions/Control_7 | ||
| Interventions/Control_8 | ||
| Interventions/Control_9 | ||
| Interventions/Control_10 | ||
| Eligibility | ||||
| Age-lower limit |
|
|||
| Age-upper limit |
|
|||
| Gender | Male and Female | |||
| Key inclusion criteria | i) Pathologically proven nasopharyngeal cancer based on the biopsy from the tumor or metastatic lymph nodes (either type I, II or III by WHO classification 1978 is eligible) ;
ii) Clinical stage II-IVB (UICC 7th edition, 2009) ; iii) Aged 20 to 75 years old; iv) ECOG PS of 0 or 1; v) No prior chemotherapy against any malignancies, no prior radiation therapy for brain, head or neck resion, no prior surgery for head and neck cancer; vi) Sufficeient organ functions; vii) No ECG abnormalities; viii) Written informed consent. |
|||
| Key exclusion criteria | i) Simultaneous or metachronous (within 5 years) double cancers;
ii) Systemic infections disease; iii) Body temperature of 38C or higher; iv) Women during pregnancy or breast-feeding; v) Psychiatric disease and/or depression; vi) Continuous systemic steroids medication; vii) Histoty of collagen diseases including rheumatism; viii) Uncontrollable diabetes mellitus or continuous administration of insulin; ix) treated with hemodialysis; x) Serious complications (COPD, pulmonary fibrosis, heart failure, etc.); xi) Myocardial infarction within 6 months or unstable angina pectoris. |
|||
| Target sample size | 75 | |||
| Research contact person | |||||||
| Name of lead principal investigator |
|
||||||
| Organization | Kinki University Faculty of Medicine | ||||||
| Division name | Department of Radiation Oncology | ||||||
| Zip code | |||||||
| Address | 377-2, Ono-higashi, Osaka-Sayama, Osaka, 589-8511, Japan | ||||||
| TEL | 072-366-0221 | ||||||
| ynishi@med.kindai.ac.jp | |||||||
| Public contact | |||||||
| Name of contact person |
|
||||||
| Organization | JCOG1015 Coordinating Office | ||||||
| Division name | Department of Radiation Oncology, Kinki University Faculty of Medicine | ||||||
| Zip code | |||||||
| Address | 377-2, Ono-higashi, Osaka-Sayama, Osaka, 589-8511, Japan | ||||||
| TEL | 072-366-0221 | ||||||
| Homepage URL | http://www.jcog.jp/ | ||||||
| JCOG_sir@ml.jcog.jp | |||||||
| Sponsor | |
| Institute | Japan Clinical Oncology Group (JCOG) |
| Institute | |
| Department | |
| Funding Source | |
| Organization | Ministry of Health, Labour and Welfare |
| Organization | |
| Division | |
| Category of Funding Organization | |
| Nationality of Funding Organization | Japan |
| Other related organizations | |
| Co-sponsor | |
| Name of secondary funder(s) | |
| IRB Contact (For public release) | |
| Organization | |
| Address | |
| Tel | |
| Secondary IDs | |
| Secondary IDs | NO |
| Study ID_1 | |
| Org. issuing International ID_1 | |
| Study ID_2 | |
| Org. issuing International ID_2 | |
| IND to MHLW | |
| Institutions | |
| Institutions | 北海道大学病院(北海道)
札幌医科大学(北海道) 国立がん研究センター東病院(千葉県) 千葉県がんセンター(千葉県) 国立がん研究センター中央病院(東京都) がん研究会有明病院(東京都) 愛知県がんセンター中央病院(愛知県) 京都大学医学部附属病院(京都府) 近畿大学医学部(大阪府) 大阪府立病院機構大阪府立成人病センター(大阪府) 広島大学病院(広島県) |
| Other administrative information | |||||||
| Date of disclosure of the study information |
|
||||||
| Related information | |
| URL releasing protocol | |
| Publication of results | Unpublished |
| Result | |
| URL related to results and publications | |
| Number of participants that the trial has enrolled | |
| Results | |
| Results date posted | |
| Results Delayed | |
| Results Delay Reason | |
| Date of the first journal publication of results | |
| Baseline Characteristics | |
| Participant flow | |
| Adverse events | |
| Outcome measures | |
| Plan to share IPD | |
| IPD sharing Plan description | |
| Progress | |||||||
| Recruitment status | Completed | ||||||
| Date of protocol fixation |
|
||||||
| Date of IRB |
|
||||||
| Anticipated trial start date |
|
||||||
| Last follow-up date |
|
||||||
| Date of closure to data entry | |||||||
| Date trial data considered complete | |||||||
| Date analysis concluded | |||||||
| Other | |
| Other related information | |
| Management information | |||||||
| Registered date |
|
||||||
| Last modified on |
|
||||||
| Link to view the page | |
| URL(English) | https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000006118 |